Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.

ABSTRACT:

Purpose

Increased availability of next-generation sequencing has allowed for the genomic characterization of a variety of pediatric tumors, although genomic determinants of response to treatment remain largely unknown. We sought to evaluate the genomic landscape and genomic determinants of clinical outcomes in rhabdomyosarcoma (RMS).

Experimental design

Of 29,067 patients who underwent genomic profiling at our institution using a 468-gene oncopanel with complete records, 87 had RMS, of whom 22 were fusion positive. The 10 most common genetic alterations were associated with locoregional control (LC), disease-free survival (DFS), and overall survival (OS). Tumor mutational burden (TMB), defined as the total number of somatic nonsynonymous mutations normalized to the number of

SUBMITTER: Casey DL 

PROVIDER: S-EPMC8693250 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature